NSB Stock Overview
Develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NeuroScientific Biopharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.043 |
| 52 Week High | AU$0.14 |
| 52 Week Low | AU$0.035 |
| Beta | 0.49 |
| 1 Month Change | -18.87% |
| 3 Month Change | 19.44% |
| 1 Year Change | -56.57% |
| 3 Year Change | -86.56% |
| 5 Year Change | -69.29% |
| Change since IPO | -80.89% |
Recent News & Updates
Recent updates
Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?
May 25
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth
Jan 27NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans
Oct 07Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth
Jun 23Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth
Mar 10We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely
Nov 18Shareholder Returns
| NSB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -6.5% | -1.4% | 1.1% |
| 1Y | -56.6% | -7.9% | 9.4% |
Return vs Industry: NSB underperformed the Australian Biotechs industry which returned -7.9% over the past year.
Return vs Market: NSB underperformed the Australian Market which returned 9.4% over the past year.
Price Volatility
| NSB volatility | |
|---|---|
| NSB Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: NSB's share price has been volatile over the past 3 months.
Volatility Over Time: NSB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | n/a | www.neuroscientific.com |
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company’s lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.
NeuroScientific Biopharmaceuticals Limited Fundamentals Summary
| NSB fundamental statistics | |
|---|---|
| Market cap | AU$6.36m |
| Earnings (TTM) | AU$761.17k |
| Revenue (TTM) | AU$3.79m |
8.2x
P/E Ratio1.6x
P/S RatioIs NSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NSB income statement (TTM) | |
|---|---|
| Revenue | AU$3.79m |
| Cost of Revenue | AU$47.88k |
| Gross Profit | AU$3.75m |
| Other Expenses | AU$2.99m |
| Earnings | AU$761.17k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0053 |
| Gross Margin | 98.74% |
| Net Profit Margin | 20.06% |
| Debt/Equity Ratio | 0% |
How did NSB perform over the long term?
See historical performance and comparison